Development

Research into Cold Cancers Heating Up

Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Proprietary Cell-Line Development for High-Titer AAV Manufacturing

Proprietary cell lines offer opportunities for achieving high AAV titers.

Bracing for a Future Wave of Advanced Therapies

In the ATMP space, CGTs are hitting their stride with unprecedented approvals in the past year alone.

Exploring Innovative Means for Biologics Delivery

September 10, 2024

Alternative delivery methods for biologics continues to be explored that offer less invasive, less painful administration.

Biobetter Development

September 08, 2024

Weighing development costs/resources and performance benefits is essential.

Leveraging Bioanalytical Studies Advancements

September 04, 2024

As the field of bioanalytical testing evolves, it is important for drug developers to stay at the forefront of the advancements to ensure they remain competitive.

Lilly Completes $3.2 Billion Acquisition of Morphic, Boosting Its IBD Pipeline

August 27, 2024

With the completion of its acquisition of Morphic, Lilly expands its immunology pipeline to include Morphic's oral integrin therapies to address inflammatory bowel disease.

Webcasts

Advances in mAb Purification with Super A Chromatography Resin

August 27, 2024

Webinar Date/Time: Thurs, September 19, 2024 Session 1: 9:00am EDT | 1:00pm GMT | 2:00pm CET Session 2: 1:00pm EDT| 5:00pm GMT | 6:00 am CET

Webcasts